Table 2.
Clinicopathological characteristics by ctDNA result (n = 88)
| Characteristics | Negative (n = 47) n (%) | Positive (n = 41) n (%) | P value |
|---|---|---|---|
| Sex | |||
| Male | 21 (44.7) | 20 (48.8) | 0.701 |
| Female | 26 (55.3) | 21 (51.2) | |
| Median age (min-max) | 59 (27-80) | 55 (35-78) | 0.558 |
| Cancer type | |||
| Colorectal cancer | 45 (95.7) | 35 (85.4) | 0.224 |
| Gastric cancer | 1 (2.1) | 4 (9.8) | |
| Esophageal cancer | 1 (2.1) | 2 (4.9) | |
| Cancer stagea | |||
| Stage I | 5 (10.6) | 3 (7.3) | 0.487 |
| Stage II | 11 (23.4) | 14 (34.2) | |
| Stage III | 20 (42.6) | 12 (29.3) | |
| Stage IV | 11 (23.4) | 12 (29.3) | |
| Treatment status at first ctDNA test | |||
| Chemotherapy/immunotherapy | 3 (6.4) | 20 (48.8) | <0.001 |
| Post-surgery | 14 (29.8) | 8 (19.5) | |
| Pre-surgery | 4 (8.5) | 10 (24.4) | |
| Surveillance | 26 (55.3) | 3 (7.3) |
a
Staging at baseline based on the American Joint Committee on Cancer (AJCC) TNM (tumor–node–metastasis) staging system.